tiprankstipranks
Silexion Therapeutics (SLXN)
NASDAQ:SLXN
US Market
Holding SLXN?
Track your performance easily

Silexion Therapeutics (SLXN) Income Statement

21 Followers

Silexion Therapeutics Income Statement

Last quarter (Q ), Silexion Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Silexion Therapeutics's net income was $1.37M. See Silexion Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
---$ 0.00$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 237.00K$ 4.68M$ 3.86M$ 943.93K$ 195.86K
Operating Income
$ -237.00K$ -4.68M$ -3.86M$ -943.93K$ -195.86K
Net Non Operating Interest Income Expense
$ 520.02K$ 144.00K$ -199.00K$ 6.37K$ 0.00
Other Income Expense
$ 9.56K$ 86.00K$ 1.02M$ 182.34K-
Pretax Income
$ 1.71M$ -5.08M$ -5.73M$ -755.22K$ -195.86K
Tax Provision
$ -5.00K$ 32.00K$ -24.00K--
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ 1.67M$ -4.94M$ -5.97M$ -755.22K$ -195.86K
Basic EPS
$ 5.53$ 19.57$ 12.74$ -0.23$ -0.07
Diluted EPS
$ 5.46$ 19.57$ 12.74$ -0.23$ -0.07
Basic Average Shares
$ 3.61M$ 252.46K$ 252.37K$ 3.30M$ 2.88M
Diluted Average Shares
$ 15.11M$ 252.46K$ 252.37K$ 13.18M$ 2.88M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 237.00K$ 4.68M$ 3.86M$ 943.93K$ 195.86K
Net Income From Continuing And Discontinued Operation
$ 1.67M$ -4.94M$ -5.97M$ -755.22K$ -195.86K
Normalized Income
$ 1.70M$ -3.73M$ -5.75M$ -937.56K$ -195.86K
Interest Expense
-----
EBIT
$ 1.18M$ -5.22M$ -5.61M$ -943.93K$ -195.86K
EBITDA
$ 1.19M$ -5.18M$ -5.55M$ -943.93K$ -195.86K
Currency in USD

Silexion Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis